'Selective' JDRF Backs Israeli Injectable Blood Glucose Monitor
Executive Summary
An Israeli start-up developing an injectable, miniature continuous blood glucose monitoring implant has secured funding from the Juvenile Diabetes Research Foundation (JDRF) to speed up product development. The investment will be used to bring GluSense closer to its first in-human clinical trial.
You may also be interested in...
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
Abbott Surprises Analysts With CE Mark For Freestyle Libre 3
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.